Altamira Therapeutics Ltd. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$2.22 | -$2.22 | -$2.22 |
| Q2 2024 | 1 | -$545.29 | -$545.29 | -$545.29 |
| Q3 2024 | 1 | -$433.95 | -$433.95 | -$433.95 |
| Q1 2025 | 1 | -$433.95 | -$433.95 | -$433.95 |
| Q2 2025 | 1 | -$372.90 | -$372.90 | -$372.90 |
| Q1 2026 | 1 | -$2.02 | -$2.02 | -$2.02 |
| Q2 2026 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q1 2027 | 1 | -$0.44 | -$0.44 | -$0.44 |
| Q2 2027 | 1 | -$0.47 | -$0.47 | -$0.47 |
Altamira Therapeutics Ltd. Earnings Date And Information
Altamira Therapeutics Ltd. last posted its earnings results on Thursday, April 16th, 2020. The company reported $-119.25205 earnings per share for the quarter, missing analysts' consensus estimates of $-32 by $87.25205. The company had revenue of 52,735 for the quarter and had revenue of 0 for the year. Altamira Therapeutics Ltd. has generated $-15 earnings per share over the last year ($-14.8 diluted earnings per share) and currently has a price-to-earnings ratio of -0.03. Altamira Therapeutics Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 9th, 2025 based on prior year's report dates.
Altamira Therapeutics Ltd. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 06/28/2023 | Q2 2023 | -$12.91 | $52,735 | |||
| 03/30/2023 | Q1 2023 | -$12.97 | $52,735 | |||
| 05/16/2023 | Q4 2022 | -$2.89 | $0 | |||
| 09/29/2022 | Q3 2022 | -$199.86 | $-458,691 | |||
| 11/30/2022 | Q2 2022 | -$106.32 | $145,399 | |||
| 11/30/2022 | Q1 2022 | -$106.32 | $145,399 | |||
| 04/12/2022 | Q4 2021 | $164.89 | $0 | |||
| 09/29/2021 | Q3 2021 | -$149.92 | $0 | |||
| 03/31/2021 | Q2 2021 | -$108.47 | $0 | |||
| 03/31/2021 | Q1 2021 | -$108.47 | $0 | |||
| 03/31/2021 | Q4 2020 | -$148.91 | $237,000 | |||
| 09/29/2020 | Q3 2020 | -$148.91 | $0 | |||
| 09/17/2020 | Q2 2020 | -$115.96 | $0 | |||
| 09/17/2020 | Q1 2020 | -$115.96 | $0 | |||
| 04/16/2020 | Q4 2019 | -$32.00 | -$83.44 | -51.44 | $-56,000 | |
| 09/29/2019 | Q3 2019 | $0.00 | $0 | |||
| 06/30/2019 | Q2 2019 | -$165.85 | $0 | |||
| 03/30/2019 | Q1 2019 | $0.00 | $0 | |||
| 03/14/2019 | Q4 2018 | -$485.21 | $1.27 M | |||
| 09/30/2018 | Q3 2018 | -$569.22 | $0 |
Altamira Therapeutics Ltd. Earnings: Frequently Asked Questions
-
When is Altamira Therapeutics Ltd.'s earnings date?
Altamira Therapeutics Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 9th, 2025 based off last year's report dates.
-
How can I listen to Altamira Therapeutics Ltd.'s earnings conference call?
The conference call for Altamira Therapeutics Ltd.'s latest earnings report can be listened to online.
-
How can I read Altamira Therapeutics Ltd.'s conference call transcript?
The conference call transcript for Altamira Therapeutics Ltd.'s latest earnings report can be read online.
-
How much profit does Altamira Therapeutics Ltd. generate each year?
Altamira Therapeutics Ltd. (:CYTO) has a recorded net income of $0. Altamira Therapeutics Ltd. has generated $-14.81 earnings per share over the last four quarters.
-
What is Altamira Therapeutics Ltd.'s price-to-earnings ratio?
Altamira Therapeutics Ltd. (:CYTO) has a price-to-earnings ratio of -0.03 and price/earnings-to-growth ratio is -0.
